Pacira Presents Real-World Data on EXPAREL® Showing Lower Total Healthcare Costs in Outpatient Total Hip and Knee Arthroplasty Procedures

-- Select findings demonstrate that the use of EXPAREL® (bupivacaine liposome injectable suspension) in outpatient Total Hip Arthroplasty (THA) and Total Knee Arthroplasty (TKA) is associated with lower total healthcare costs over various follow-up periods —

-- Reduced opioid use observed at 6 months post-surgery among Medicare Advantage patients with low back pain in THA Study --

BRISBANE, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today presented data from three real-world studies supporting the economic value of EXPAREL® (bupivacaine liposome injectable suspension) in total hip arthroplasty (THA) and total knee arthroplasty (TKA) procedures performed in hospital outpatient department (HOPD) settings at the Academy of Managed Care Pharmacy (AMCP) Annual 2026 Meeting, taking place April 13-16 in Nashville, Tennessee. Across the analyses, EXPAREL use was associated with lower or comparable total healthcare costs and reduced opioid utilization in certain patient populations over follow-up periods of up to six months.

Select findings include:

• In one study, the use of EXPAREL for Total Hip Arthroplasty (THA) in hospital outpatient departments (HOPDs) was associated with lower total healthcare costs over 3 and 6 months of post-surgical follow-up.
  • More pronounced cost savings for patients with lower back pain as well as reduced opioid usage compared to patients who did not receive liposomal bupivacaine (non-LB) were also observed.
• In the second assessment, EXPAREL use during HOPD Total Knee Arthroplasty (TKA) was associated with comparable or lower healthcare costs, particularly in teaching hospitals.
• The third assessment was a three-year budget impact analysis, that found that EXPAREL use was associated with a projected cumulative absolute cost difference of −$117,868 per 1 million members by year 3 compared to ropivacaine in the HOPD Commercial and Medicare Advantage settings, with higher pharmacy acquisition costs offset by reductions in total healthcare expenditures.

“These real-world data continue to demonstrate the economic value that EXPAREL can deliver across outpatient orthopedic procedures,” said Brendan Teehan, Chief Commercial Officer of Pacira Biosciences. “By helping reduce total healthcare costs, lowering opioid use, and supporting more efficient recovery in real-world settings, these data reinforce our commitment to advancing non-opioid pain management solutions that benefit patients, providers, and payers alike. We believe these findings further support the role of EXPAREL in improving access to effective and best-practice opioid-sparing pain control while addressing the broader challenges of affordability and opioid stewardship.”

Pacira Presentations at AMCP 2026:

1. Real-World Assessment of Healthcare Expenditures and Opioid Intake Following Total Hip Arthroplasty in Medicare Advantage Beneficiaries” (Poster #363)This retrospective, real-world analysis evaluated the association between liposomal bupivacaine (LB) use and healthcare expenditures and opioid utilization over 6 months following total hip arthroplasty (THA) performed in hospital outpatient department (HOPD) settings among Medicare Advantage beneficiaries.LB use was associated with lower total healthcare costs at 3 months ($7,332 vs $8,153; P=0.007) and 6 months ($13,022 vs $15,081; P